Stock Update (NYSE:LLY): Lilly continues test of HDL cholesterol drug, on panel’s advice

[Reuters] – Eli Lilly and Co on Monday said it would continue a large study of its high-profile experimental drug to raise “good” HDL cholesterol and lower “bad” LDL cholesterol, acting on the . . . → Read More: Stock Update (NYSE:LLY): Lilly continues test of HDL cholesterol drug, on panel’s advice Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – FDA asks panel to weigh benefit, risk of Lilly lung cancer drug Market Update (NYSE:LLY): Eli Lilly wins UK Alimta drug patent case on appeal Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis